The NuGenHealth Software as a Service (SaaS) System Remote

New Post Public Reply Private Reply Replies (1) Message Board
docj
430
The NuGenHealth Software as a Service (SaaS) System
Remote Patient Monitoring (RPM)
Chronic Care Management (CCM)
The access information for the investor conference call remains as follows:
Direct Toll / International – 1-(866) 831-8711
Domestic US/Canada - 1-(203) 518-9883
Program Title: Generex Biotechnology Conference Call
Conference ID – 89636

MIRAMAR, Fla., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company’s wholly owned subsidiary NuGenerex Health LLC has signed a joint venture agreement with Worldwide Digitech, LLC (WWDT) to form NuGenHealth LLC. Under terms of the 50/50 JV agreement, WWDT will provide the software powered by the HealthKOS framework and back-end support for the NuGenHealth SaaS system.

The goals of NuGenHealth are to provide connected care solutions for patient engagement, Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) to physicians, hospitals, and other providers of patient care, and to improve patient health outcomes at reduced costs.

New CPT Codes released by CMS in 2019 provide an incentive for physicians to offer better management of chronic conditions using Remote Patient Monitoring. The new rules make it easier for physicians and healthcare organizations to partner with health-tech companies to provide the services, software and monitoring devices required to launch a successful RPM program.

Chronic Care Management (CCM) is a service designed to pay separately for non-face-to-face care coordination services furnished to part B Medicare beneficiaries with multiple chronic conditions.

NuGenHealth is an end-to-end solution that was developed by doctors to improve patient engagement, compliance and outcomes. The system provides direct savings to the physician and healthcare organizations both in time and money as well as improving patient outcomes. What makes NuGenHealth different is that it utilizes automated algorithms, real-time data, and quality metrics to involve patients in their own care, as well as keeping healthcare providers and family constantly informed. NuGenHealth allows the healthcare team to monitor patient progress outside the practice office, leading to timely interventions that prevent disease progression and unnecessary hospitalizations.

Joe Moscato, President & CEO of Generex, said, “We have evaluated a number of software systems and companies that claim to deliver the care coordination services, but the WWDT SaaS system far surpassed the others in terms of functionality, connections with electronic health record systems, real-time remote monitoring capabilities with connected health monitoring devices, protocols for RPM and CCM, and a fantastic user interface. We plan to launch the system with primary care and endocrinology clinics in Arizona to begin generating revenues as we launch the company. We are happy to be working with excellent partners in WWDT to implement the NuGenHealth system.”

Dr. Goel commented, “I am extremely glad to partner with Joe and his team. The ability to bring connected care to patients, will improve the delivery of Healthcare and improve the quality of care for patient and allow the physician to be more efficient.”

“Patient engagement and Remote Patient Monitoring have become the cornerstones of exciting new approaches to preventative, accountable health care. With the Launch of NGH, we will be able to enable provider organization to put these exciting new models of innovation into practice. I am very glad to be part of this new organization and help transform healthcare for the benefit of patients.”

“By leveraging Care Coordination teams and the NGH Platform, High Risk patients can now be actively engaged in the remote care process and monitoring on a 24x7 basis, resulting in better quality of care, reducing 30 day readmission rates, while reducing the total cost of care. It is a great privilege to be able to bring this technology to market, knowing the improvement to patient care that can be achieved.”

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Arianna Huffington's Journey: Redefining Success Through Wellbeing

Updated Category News Views 309

Arianna Huffington's Experience with Overworking Arianna Huffington is widely recognized for launching The Huffington Post news website in 2005. However, her journey took a significant turn just two years later when she suffered a collapse in her office due to extreme exhaustion and lack of sleep. This pivotal moment compelled Huffington to rethink the culture of...

Continue Reading
Key Insights into Rathbones Group Plc's Position in Learning Tech

Updated Category News Views 66

Understanding Public Opening Position Disclosures In the realm of financial markets, ensuring transparency is crucial. Public opening position disclosures allow market participants to learn about the interests of individuals and entities in significant securities. One such disclosure recently made headlines as Rathbones Group Plc announced its positions in Learning...

Continue Reading
How a Chicken Finger Chain Became a Billion-Dollar Success

Updated Category News Views 345

Todd Graves launched Raising Cane's back in 1996, defying critics who claimed a chicken finger-only menu wouldn’t fly. I mean, come on—banks tossed him aside like last week's stale fries when he tried to secure funding. Imagine that skepticism ringing through Louisiana's south: all they saw was a niche that couldn’t possibly sustain itself. But here’s the kicker:...

Continue Reading
How a $1000 Investment in Orla Mining Could Grow Over Time

Updated Category News Views 126

Exploring the Growth of Orla Mining Investments Orla Mining has shown remarkable performance in the stock market, with an annual increase of 5.29% compared to the wider market over the past five years, delivering an average annual return of 18.92%. Investors are certainly intrigued by the growth factors contributing to a market capitalization of $3.65 billion. Investment...

Continue Reading
Celestica's Upcoming Financial Results and Investor Day Preview

Updated Category News Views 371

Celestica's Announcement for Q3 2025 Financial Results Celestica Inc. (TSX and NYSE: CLS) is gearing up for its third quarter 2025 financial results conference call and an exciting Investor and Analyst Day. The scheduled call will take place on a Tuesday morning soon after the market closes, providing valuable insights to participants. Conference Call Details The...

Continue Reading